Anatomic pathology selected abstracts
April 2026—CAR T-cell therapy-related gastrointestinal toxicity: histologic features and morphologic mimics; Clinicopathologic and genomic characterization of granuloma-rich hepatocellular carcinoma
Webinars and Commercial Conversations — Register Now
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
April 2026
Molecular pathology selected abstracts
April 2026—Use of long-read sequencing to monitor diagnostic blind spots of inherited metabolic diseases; Diffuse large B-cell lymphoma: a biologically heterogenous disease
Pathology informatics selected abstracts
April 2026—Technical considerations during validation of Genius digital diagnostic system; Applicability of accreditation requirements to machine learning-based methods in molecular oncology testing
Q&A column
April 2026
Q. Do regulatory agencies still support sodium citrate platelet counts? What is the CAP’s standing? Read answer.
Newsbytes
April 2026—PathGroup, a clinical laboratory, partnered with Labgnostic to automate proficiency testing order entry and result delivery. LabgnosticPT, an application from Labgnostic, automates the PT process, integrating with laboratory information systems for seamless order and result transmission. This automation significantly reduces administrative time, allowing PathGroup staff to focus more on patient-centered work.
Put It on the Board
April 2026—Vitestro raised $70 million in Series B financing to advance its Aletta robotic phlebotomy device. The funding will support product development, manufacturing, clinical expansion, and commercial readiness for the Aletta, which uses imaging, robotics, and AI for blood collection.